Lucas Ferrari de Andrade

Dr. Lucas Ferrari de Andrade


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2018 in Science
Verified
Journal Article
Closed access
PDF file
DPDeng Pan
Deng Pan
AKAya Kobayashi
Aya Kobayashi
PJPeng Jiang
Peng Jiang
LALucas Ferrari de Andrade
Lucas Ferrari de Andrade
RTRong En Tay
Rong En Tay
KWKai W. Wucherpfennig
Kai W. Wucherpfennig
SNF'ing out antitumor immunity: Immune checkpoint inhibitors induce durable tumor regressions in some, but not all, cancer patients. Understanding the mechanisms that determine tumor sensitivity to these drugs could potentially expand the number of patients who benefit (see the Perspective by Ghorani and Quezada). Pan et al. discovered that tumor cells in which a specific SWI/SNF chromatin remodeling complex had been experimentally inactivated were more sensitive to T cell–mediated killing. The cells were more responsive to interferon-γ, leading to increased secretion of cytokines that promote antitumor immunity. Miao et al. examined the genomic features of tumors from patients with metastatic renal cell carcinoma who had been treated with immune checkpoint inhibitors. Tumors harboring inactivating mutations in PBRM1 , which encodes a subunit of the same SWI/SNF complex, were more likely to respond to the drugs. Science , this issue p. 770 , p. 801 ; see also p. 745

30 March 2018 in Science
Verified
Journal Article
Open access
PDF file
LALucas Ferrari de Andrade
Lucas Ferrari de Andrade
RTRong En Tay
Rong En Tay
DPDeng Pan
Deng Pan
ALAdrienne M. Luoma
Adrienne M. Luoma
YIYoshinaga Ito
Yoshinaga Ito
KWKai W. Wucherpfennig
Kai W. Wucherpfennig
Helping NK cells find their way: MICA and MICB proteins can be expressed on tumors and act as “kill me” signals to the immune system. But tumors often disguise themselves by shedding these proteins, which prevents specialized natural killer (NK) cells from recognizing and destroying the cancer. Ferrari de Andrade et al. engineered antibodies directed against the site responsible for the proteolytic shedding of MICA and MICB (see the Perspective by Cerwenka and Lanier). The approach effectively locked MICA and MICB onto tumors so that NK cells could spot them for elimination. The antibodies exhibited preclinical efficacy in multiple tumor models, including humanized melanoma. Furthermore, the strategy reduced lung cancer metastasis after NK cell–mediated tumor lysis. Science , this issue p. 1537 ; see also p. 1460

5 December 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
LALucas Ferrari de Andrade
Lucas Ferrari de Andrade
YLYuheng Lu
Yuheng Lu
ALAdrienne Luoma
Adrienne Luoma
YIYoshinaga Ito
Yoshinaga Ito
DPDeng Pan
Deng Pan
KWKai W. Wucherpfennig
Kai W. Wucherpfennig
NK cells contribute to protective antitumor immunity, but little is known about the functional states of NK cells in human solid tumors. To address this issue, we performed single-cell RNA-seq analysis of NK cells isolated from human melanoma metastases, including lesions from patients who had progressed following checkpoint blockade. This analysis identified major differences in the transcriptional programs of tumor-infiltrating compared with circulating NK cells. Tumor-infiltrating NK cells represented 7 clusters with distinct gene expression programs indicative of significant functional specialization, including cytotoxicity and chemokine synthesis programs. In particular, NK cells from 3 clusters expressed high levels of XCL1 and XCL2 , which encode 2 chemokines known to recruit XCR1 + cross-presenting DCs into tumors. In contrast, NK cells from 2 other clusters showed a higher level of expression of cytotoxicity genes. These data reveal key features of NK cells in human tumors and identify NK cell populations with specialized gene expression programs.

1 January 2020 in Clinical & Translational Immunology
Verified
Journal Article
Open access
PDF file
SXSamantha Xing
Samantha Xing
LALucas Ferrari de Andrade
Lucas Ferrari de Andrade
Natural killer (NK) cells are innate lymphocytes with cytotoxic functions and recognise target cells with the NK group 2D (NKG2D) receptor. Tumor cells are marked for NK‐cell‐mediated destruction upon expression of MICA and MICB (MICA/B), which are NKG2D ligands upregulated by many human cancers in response to cellular stress pathways associated with malignant transformation such as DNA damage and accumulation of misfolded proteins. However, MICA/B proteins are downregulated by tumor cells via intriguing molecular mechanisms, such as post‐translational modifications in which the external domains of MICA/B are proteolytically cleaved by surface proteases and shed into the extracellular space. MICA/B shedding by cancer cells causes effective escape from NKG2D recognition and allows the development of cancers. Patients frequently have increased concentrations of soluble MICA/B molecules shed in the blood plasmas and sera, thus indicating that MICA/B shedding is a therapeutic target in immune‐oncology. Here, we review the clinical significance of MICA/B shedding in cancer as well as novel immunotherapeutic approaches that aim to restore NKG2D‐mediated surveillance. We also briefly discuss potential roles of MICA/B shedding beyond oncology, such as in viral infections and immune tolerance. This review will help to inform the future developments of NKG2D‐based immunotherapies.

1 April 2015 in Cell Reports
Verified
Journal Article
Open access
LMLudovic Martinet
Ludovic Martinet
LALucas Ferrari de Andrade
Lucas Ferrari de Andrade
CGCamille Guillerey
Camille Guillerey
Jason S. LeeJason S. Lee
Jason S. Lee
JLJing Liu
Jing Liu
MSMark J. Smyth
Mark J. Smyth
Natural killer (NK) cells comprise a heterogeneous population of cells important for pathogen defense and cancer surveillance. However, the functional significance of this diversity is not fully understood. Here, we demonstrate through transcriptional profiling and functional studies that the activating receptor DNAM-1 (CD226) identifies two distinct NK cell functional subsets: DNAM-1(+) and DNAM-1(-) NK cells. DNAM-1(+) NK cells produce high levels of inflammatory cytokines, have enhanced interleukin 15 signaling, and proliferate vigorously. By contrast, DNAM-1(-) NK cells that differentiate from DNAM-1(+) NK cells have greater expression of NK-cell-receptor-related genes and are higher producers of MIP1 chemokines. Collectively, our data reveal the existence of a functional program of NK cell maturation marked by DNAM-1 expression.

17 December 2013 in Immunology & Cell Biology
Verified
Journal Article
Closed access
PDF file
LALucas Ferrari de Andrade
Lucas Ferrari de Andrade
MSMark J Smyth
Mark J Smyth
LMLudovic Martinet
Ludovic Martinet